Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.47 |
| ▸ | MET | P08581 | 5/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2750077 | 0.92 | BTK (0.46) | BTKMETPDK2MAPTMEN1 | |
| SCHEMBL2748462 | 0.89 | MET (0.50) | BTKMETPDK2MAPTMEN1 | |
| SCHEMBL2748423 | 0.89 | MET (0.50) | BTKMETPDK2MAPTMEN1 | |
| SCHEMBL2750045 | 0.89 | MET (0.49) | BTKMETPDK2MAPTMEN1 | |
| SCHEMBL2749325 | 0.88 | MAPK1 (0.47) | BTKMETMAPTMEN1KMT2A | |
| SCHEMBL2749608 | 0.88 | MET (0.47) | METPDK2MAPTMEN1KMT2A | |
| SCHEMBL2751069 | 0.86 | MET (0.44) | METMAPTNPC1RAB9AMAPK1 | |
| SCHEMBL2749424 | 0.85 | MET (0.49) | METPDK2MAPTMEN1KMT2A | |
| SCHEMBL2749147 | 0.84 | MET (0.46) | BTKMETPDK2MAPTMEN1 | |
| SCHEMBL2749226 | 0.84 | CCNC (0.47) | METPDK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | BTK 316/4885MET 38/4885PDK2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.